-- Mesoblast（ASX：MSB）週四向澳洲證券交易所提交的文件顯示，其間質幹細胞產品Ryoncil在3月季度的總銷售額為3,530萬美元。 文件也顯示，淨收入為3,030萬美元，使得該產品上市第一年的收入接近1億美元。 3月季度的客戶收入為3,460萬美元，去年同期僅150萬美元。 Mesoblast的股價在周四的交易中下跌了近5%。
Related Articles
International
Saudi Arabia's Quarterly GDP Down 1.5% in Q1, Flash Data Shows
Saudi Arabia's seasonally adjusted real gross domestic product decreased 1.5% on a quarterly basis in the first quarter, compared with a 1.4% rise in the prior three-month period, flash data from the General Authority for Statistics showed Thursday.Annually, the Saudi Arabian economy grew 2.8% during the three-month period, after a 5% increase in the previous quarter.
$^TASI
Asia
Diagens Biotechnology's 2025 Loss Widens
Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.
$HKG:2526
Asia
Daqin Railway Q1 Profit Down 7%; Shares Slip 3%
Daqin Railway Co (SHA:601006) posted first-quarter attributable net profit of 2.38 billion yuan, down 6.9% from 2.56 billion yuan the previous year.Earnings per share slid to 0.12 yuan from 0.13 yuan, according to a Thursday filing with the Shanghai bourse.Operating revenue climbed 4.3% year over year to 18.6 billion yuan from 17.8 billion yuan.Shares of the railway operator declined 3% in recent trade.
$SHA:601006